Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026)
Gilead Sciences' (GILD) quarterly Income towards Parent Company came in at -$10.5 billion in Q2 2026, down 635.24% on a YoY basis from $2.0 billion in Q2 2025, and down 619.35% quarter-over-quarter from $2.0 billion in Q1 2026.
Analysis
Gilead Sciences (GILD) Income towards Parent Company (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Income towards Parent Company for 18 consecutive years, with -$10.5 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income towards Parent Company fell 635.24% year-over-year to -$10.5 billion; the trailing twelve-month figure through Jun 2026 stood at -$2.9 billion (down 145.87% YoY), and the FY2025 full-year result was $8.5 billion, up 1676.62% from the prior year.
- Income towards Parent Company slipped to -$10.5 billion in Q2 2026 per GILD's latest filing, from $2.0 billion in the prior quarter.
- Across five years, Income towards Parent Company topped out at $3.1 billion in Q3 2025 and bottomed at -$10.5 billion in Q2 2026.
- Historically, Income towards Parent Company has averaged $613.2 million across 5 years, with a median of $1.5 billion in 2023.
- The sharpest annual moves came in 2023 and 2026: Income towards Parent Company surged 8100.0% in 2023, then slumped 635.24% in 2026.
- Over 5 years, Income towards Parent Company stood at $1.6 billion in 2022, then fell by 13.29% to $1.4 billion in 2023, then grew by 25.85% to $1.8 billion in 2024, then surged by 41.86% to $2.5 billion in 2025, then tumbled by 515.19% to -$10.5 billion in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$10.5 billion, $2.0 billion, and $2.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.50 Bn |
| Mar 31, 2026 | 2.02 Bn |
| Dec 31, 2025 | 2.53 Bn |
| Sep 30, 2025 | 3.05 Bn |
| Jun 30, 2025 | 1.96 Bn |
| Mar 31, 2025 | 1.32 Bn |
| Dec 31, 2024 | 1.78 Bn |
| Sep 30, 2024 | 1.25 Bn |
| Jun 30, 2024 | 1.62 Bn |
| Mar 31, 2024 | -4.17 Bn |
| Dec 31, 2023 | 1.42 Bn |
| Sep 30, 2023 | 2.17 Bn |
| Jun 30, 2023 | 1.04 Bn |
| Mar 31, 2023 | 984.00 Mn |
| Dec 31, 2022 | 1.63 Bn |
| Sep 30, 2022 | 1.79 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 12.00 Mn |
| Dec 31, 2021 | 376.00 Mn |
| Sep 30, 2021 | 2.59 Bn |